TL;DR
This paper introduces an adaptive trial design that dynamically chooses between a composite endpoint and its most relevant component based on blinded interim data, optimizing sample size and maintaining power.
Contribution
It proposes a novel adaptive design allowing endpoint selection and sample size reassessment based on blinded information, improving trial efficiency and robustness.
Findings
Adaptive design maintains power even with correlation misspecification
Sample size is optimized by selecting the most relevant endpoint
Design achieves targeted power while controlling type 1 error
Abstract
For randomized clinical trials where a single, primary, binary endpoint would require unfeasibly large sample sizes, composite endpoints are widely chosen as the primary endpoint. Despite being commonly used, composite endpoints entail challenges in designing and interpreting results. Given that the components may be of different relevance and have different effect sizes, the choice of components must be made carefully. Especially, sample size calculations for composite binary endpoints depend not only on the anticipated effect sizes and event probabilities of the composite components, but also on the correlation between them. However, information on the correlation between endpoints is usually not reported in the literature which can be an obstacle for planning of future sound trial design. We consider two-arm randomized controlled trials with a primary composite binary endpoint and an…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
